NCT05774756Active, not recruitingPhase 3
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.45 sites in 6 countries143 target enrollmentStarted: April 26, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 143
- Locations
- 45
- Primary Endpoint
- Mean % change in BMI
Study Overview
Brief Summary
The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for 52 weeks on a therapeutic regimen.
A separate sub-study in patients with congenital HO is detailed under NCT06760546.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 4 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Documented evidence of acquired hypothalamic obesity (HO)
- •Age 4 years and older
- •Weight gain associated with the hypothalamic injury and a BMI of ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th percentile for age and sex for patients 4 to <18 years of age
- •Agree to use a highly effective form of contraception throughout the study and for 90 days after the study
Exclusion Criteria
- •Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET)
- •Weight loss >2% in the previous 3 months for patients aged ≥18 years or >2% reduction in BMI for patients aged 4 to <18 years
- •Bariatric surgery or procedure within last 2 years
- •Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior
- •Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease
- •Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
- •History or close family history of skin cancer or melanoma
- •Participation in any clinical trial with an investigational drug/device within 3 months prior to the first trial dose
- •Previously enrolled in a clinical trial involving setmelanotide or any previous exposure to setmelanotide
- •Inability to comply with once daily (QD) injection regimen
- •If female, pregnant and/or breastfeeding
- •Patients with obesity attributable to other genetic or syndromic conditions (eg, PPL [POMC, PCSK1, LEPR, collectively], BBS) prior to the hypothalamic injury.
- •If receiving hormone replacement therapy, dose has remained stable for at least 2 months before Screening
- •Other protocol defined Inclusion/Exclusion criteria may apply.
Arms & Interventions
Setemelanotide
Experimental
Randomized 2:1 (Setmelanotide: Placebo)
Intervention: Setmelanotide (Drug)
Placebo
Placebo Comparator
Randomized 2:1 (Setmelanotide: Placebo)
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Mean % change in BMI
Time Frame: From Baseline after 52 weeks on a therapeutic regimen
Secondary Outcomes
- Proportion of patients with ≥5% reduction in BMI in adult patients (≥18 years of age) or a BMI Z-score reduction of ≥0.2 points in pediatric patients (<18 years of age)(From Baseline after 52 weeks on a therapeutic regimen)
- Mean change in the weekly average of the daily most hunger score in patients ≥12 years old(From Baseline after 52 weeks on a therapeutic regimen)
- Proportion of patients with a ≥2 point reduction in the weekly average of the daily most hunger score(From Baseline after 52 weeks on a therapeutic regimen)
- Mean change in Symptoms of Hyperphagia total score(From Baseline after 52 weeks on a therapeutic regimen)
- Proportion of patients with a ≥10% reduction in BMI(From Baseline after 52 weeks on a therapeutic regimen)
- Mean percent change in weight in patients ≥18 years(From Baseline after 52 weeks on a therapeutic regimen)
- Mean BMI-z score and BMI percentile reduction in patients <18 (using combined height and weight to report BMI in kg/m2)(From Baseline after 52 weeks on a therapeutic regimen)
- Proportion of patients aged ≥4 to <18 years with ≥0.2-point reduction of BMI Z-score(From Baseline after 52 weeks on a therapeutic regimen)
- Proportion of patients with BMI <30 kg/m2 (patients aged ≥18 years) or <95th percentile (patients aged <18 years)(From Baseline after 52 weeks on a therapeutic regimen)
- Mean change in physical functioning score and total score for the Impact of Weight on Quality of Life-Lite (IWQOL)(From Baseline after 52 weeks on a therapeutic regimen)
- Safety and tolerability of setmelanotide compared to placebo assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)(From Baseline after 52 weeks on a therapeutic regimen)
Investigators
Study Sites (45)
Loading locations...
Similar Trials
Completed
Phase 2
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityGenetic ObesityObesity Due to Melanocortin 4 Receptor DeficiencyObesityNCT03013543Rhythm Pharmaceuticals, Inc.213
Completed
Phase 4
Phase IV Study of Qsymia in Obese PatientsObesityNCT05378503Alvogen Korea232
Completed
Phase 2
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese SubjectsObesityNCT01666691Zafgen, Inc.160
Completed
Phase 3
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityBardet Biedl Syndrome (BBS)Alström Syndrome (AS)NCT03746522Rhythm Pharmaceuticals, Inc.52
Active, not recruiting
Phase 3
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell TransplantDS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple MyelomaRefractory Multiple MyelomaSmoldering Multiple MyelomaNCT00114101National Cancer Institute (NCI)460